Study: Marijuana Flower Shows Neuroprotective and Pain-Relieving Effects in Alzheimer’s Model
- The study found that marijuana flower (Cannabixir® Medium Flos) produced strong pain-relieving and neuroprotective effects in a rat model simulating Alzheimer’s-related cognitive impairment and chronic neuropathic pain.
- Cannabixir® Medium Flos showed significant, time-dependent analgesic effects in thermal pain tests, especially when combined with donepezil and tramadol, outperforming tramadol alone.
- Tissue analyses revealed that the marijuana treatment reduced neuroinflammation and cell death markers, preserved hippocampal neurons, and maintained peripheral nerve structure, demonstrating notable neuroprotective properties.
- Researchers suggest Cannabixir® Medium Flos could be a promising adjunct therapy for dementia patients with chronic neuropathic pain but emphasize the need for further research on molecular mechanisms and long-term safety.
A study published in Frontiers in Pharmacology found that marijuana flower produced strong pain-relieving and neuroprotective effects in an animal model designed to mimic both Alzheimer’s-related cognitive impairment and chronic neuropathic pain. Researchers used Cannabixir® Medium Flos, an EU-GMP-certified marijuana flower containing 15.6% THC and less than 1% CBD, to examine whether it could address multiple biological pathways involved in both conditions. The study used rats with scopolamine-induced transient cognitive impairment and chronic neuropathic pain caused by unilateral sciatic nerve ligation.
The results showed that Cannabixir® Medium Flos produced robust, time-dependent analgesic effects in thermal pain tests. The strongest response was seen when the marijuana treatment was combined with donepezil and tramadol, with that combination producing significantly longer pain-response latencies than tramadol alone. Researchers noted that the marijuana treatment had only minimal impact on mechanical sensitivity, suggesting its effects were more pronounced in certain types of pain.
Tissue analyses also found substantial neuroprotective effects. According to the study, Cannabixir® Medium Flos reduced activation of markers tied to neuroinflammation and cell death, including GFAP, Iba1, Caspase-3 and IL-6. It also helped preserve hippocampal neuronal integrity and peripheral nerve structure. The study found that marijuana, either alone or in combination with donepezil or tramadol, produced the most pronounced protective effects compared to tramadol by itself.
Researchers say the findings indicate that Cannabixir® Medium Flos may have potential as an adjunct treatment for dementia patients who also experience chronic neuropathic pain. They note that additional research is needed to better understand the underlying molecular mechanisms and to assess long-term safety and efficacy.